Note: Descriptions are shown in the official language in which they were submitted.
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
LAYERED STENT-GRAFT AND METHODS OF MAKING THE SAME
BACKGROUND OF THE INVENTION
Field of the Invention
This invention generally relates to implantable intralumenal prostheses.
More particularly, this invention relates to intralumenal prostheses having
stmt
frames surrounded by biofunctional graft layers and techniques for
manufacturing
the same.
Description of the Background
Stems-grafts have proven to be an effective medical device for minimally
invasive treatment of vascular occlusions such as atherosclerosis and
restenosis.
Stent-grafts are typically shaped as hollow cylindrical structures and
constructed
of a metal stmt with at least one non-metal coating on the stmt. The metal
stmt
provides the stmt-graft with a structural framework for mechanical support.
Non-
metal coatings add any number of functions to the stmt-graft including
delivery of
a drug, prevention of thrombi formation in the stmt-graft, and reduction of
irritation of the vessel wall as compared with the irritation caused by a bare
metal
stmt.
In U.S. Patent No. 6,165,212, Dereume et al. teach a supportive
endolumenal graft. The graft includes a braided tubular support placed over a
liner and under a cover. The support is made of metals or alloys, polymers, or
ceramics. Exemplary metals and alloys include stainless steel, titanium,
tantalum,
nitinol, Elgiloy~ and NP35N. Exemplary polymers for making the support
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
include polyurethanes, silicone rubbers, polyether, sulfones,
fluoroelastomers,
polyimides, polycarbonates, polyethylenes, polylactic acid, polyglycolic acid
and
polyacrylates. The cover and the liner are made of an elastomeric material,
preferably a polyurethane, such as a polycarbonate polyurethane, one
commercial
example of which is Corethane~ (available from Corvita Corporation of Miami,
Florida).
In U.S. Patent No. 6,139,573, Sogard et al. teach an elongate radially
expandable tubular stmt and a polymeric layer covering and conforming to the
geometry of the external surface of the stmt. A polymeric liner layer and the
external polymer layer are laminated together to form a composite structure
containing the expandable tubular stmt so as to form at least three domains of
distinct porosity in the device. The stmt may be made from a variety of
materials
including stainless steel, titanium, platinum, gold, and other bio-compatible
metals.
Sogard et al. teach that the polymeric layers are made from expanded
1 S polytetrafluoroethylene (ePTFE).
In U.S. Patent No. 6,010,530, Goicoechea teaches a self expanding stmt
encapsulated by a skin. The stmt is made of a continuous "zig-zag" nitinol
wire
wound into a plurality of concentric hoops. The skin is made of an elastomeric
polymer, such as Chronoflex (available from PolyMedica Biomaterials Inc.,
Woburn, Massachusetts).
In U.S. Patent No. 5,749,880, Banas et al. teach an encapsulated stmt
which comprises at least one stmt member concentrically interdisposed between
at least two tubular ePTFE extrudates, each of the extrudates having a
substantially uniaxial fibril microstructure oriented parallel to the
longitudinal axis
of the stmt member.
z
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
In U.S. Patent 6,156,064, Chouinard teaches a stmt-graft membrane
having at least three layers including a structural stmt layer, an inside
graft layer,
and an outside layer. The outside layer is substantially impermeable to
fluids.
The outside layer is made from a siloxane, polyurethane, polycarbonate
urethane,
polytetrafluoroethylene (PTFE), ePTFE, or combinations thereof. The graft
layer
is made from polyethylene tetraphthalate (PET), ePTFE, polycarbonate urethane
(PCU), polyurethane, or combinations thereof. The stmt filaments may be made
of Elgiloy~, Conichrome, Phynox, cobalt-chromium-molybdenum (CoCrMo),
titanium alloy, titanium-zirconium-niobium alloy, titanium-aluminum-vanadium
alloy (commercially known as TI-6A1-4V), stainless steel, nitinol, platinum,
tungsten, tantalum, or combinations thereof.
In U.S. Patent No. 5,123,917, Lee teaches an expandable intralumenal
vascular graft. Lee teaches one embodiment of the graft having an inner layer
made from PTFE or a porous polyurethane, an outer layer made of PTFE, Dacron
or a proline mesh enclosing the inner layer, and a plurality of spaced
scaffold
members positioned between the inner layer and the outer layer and made of
surgical stainless steel.
In U.S. Patent No. 5,389,106, Tower teaches a distensible frame and an
impermeable deformable membrane interconnecting portions of the frame to form
an impermeable exterior wall. The frame is made from a soft platinum wire. The
membrane is preferably made from Tactylon~ (available from Tactyl
Technologies, Inc. of Vista, California).
3
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
SUMMARY OF THE INVENTION
In accordance with one aspect of the embodiments of the invention, a
stmt-graft for biological lumen placement is provided. The stmt-graft can
include
a porous first layer for making contact with tissue of a vessel wall, a non-
porous
layer substantially encapsulating a frame, and a porous second layer. The non-
porous layer can be between the porous first layer and the porous second
layer.
In one embodiment of the present invention, the porous first layer can have
a void-to-volume ratio of about 40% to about 90%. In another embodiment, the
non-porous layer has a void-to-volume ratio of about less than 5%. In yet
another
embodiment, the porous second layer has a void-to-volume ratio of about 40% to
about 90%. In a further embodiment, the pores of the porous first and second
layers have an average pore diameter of about 1 micron to about 400 microns.
In accordance with another aspect of the embodiments of the invention, a
method for manufacturing a stmt-graft is provided. The method of manufacturing
can include forming a porous first layer on a mandrel, forming a second layer
on
the porous first layer, positioning a frame on the second layer, increasing
the
thickness of the second layer to substantially or completely encapsulate the
frame
in the second layer, and forming a porous third layer on the second layer.
In one embodiment of the present invention, the act of forming the porous
first layer includes applying a composition having a solvent, a polymer
dissolved
in the solvent, and water-soluble particles to the mandrel and removing the
solvent
and the water-soluble particles from the polymer. In another embodiment of the
present invention, the act of forming the third layer includes applying a
composition having a solvent, a polymer dissolved in the solvent, and water-
4
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
soluble particles to the second layer and removing the solvent and water-
soluble
particles from the polymer.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 illustrates a side view of an embodiment of the stmt-graft.
Figure 2 illustrates cross-section 2-2 of the embodiment of the stmt-graft
illustrated in Figure 1.
Figure 3 illustrates a close-up view of a cross-section of an embodiment of
the
outer porous layer of the stmt-graft.
Figure 4 illustrates a 500 times magnification scanning electron microscope
(SEM)
image of the surface of an embodiment of the porous outer layer of the stmt-
graft.
Figure 5 illustrates a close-up view of a cross-section of an embodiment of
the
middle non-porous layer of the stmt-graft.
Figure 6 illustrates a 500 times magnification SEM image of the surface of an
embodiment of the non-porous middle layer of the stmt-graft.
Figure 7 illustrates a 500 times magnification SEM image of the surface of an
embodiment of the porous lumenal layer of the stmt-graft.
Figures 8A-8C illustrate embodiments of a stmt used with the stmt-graft.
Figure 9 illustrates a perspective view of an embodiment of a strut used with
the
stmt-graft.
Figure 10 illustrates a side view of an embodiment of the stmt-graft.
Figure 11 illustrates a bifurcated embodiment of the stmt-graft.
Figures 12A-12F illustrate methods of compressing the stmt-graft for delivery
purposes.
s
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
Figure 13 illustrates a 40 times magnification histology slide from an animal
study
using a bare stmt as a control.
Figure 14 illustrates a 40 times magnification histology slide from an animal
study
using an embodiment of the stmt-graft.
DETAILED DESCRIPTION
Figures 1 and 2 illustrate one embodiment of a stmt-graft 10 including a
porous outer layer 12, a non-porous middle layer 14, and a porous lumenal
layer
16. The non-porous middle layer 14 contains a stmt 18 having struts 20
separated
by spaces or voids 22. The division between the porous outer layer 12 and the
non-porous middle layer 14 forms an outer seam 24. The division between the
non-porous middle layer 14 and the porous lumenal layer 16 forms an inner or
lumenal seam 26. The inside of the porous lumenal layer 16 defines a lumen 28.
The stmt-graft 10 can have a length of about 1 cm (0.39 in.) to about 10
cm (3.9 in.). In one embodiment, the stmt-graft 10 can have a length of about
3
cm (1.2 in.).
POROUS OUTER LAYER
The porous outer layer 12 can be the outer-most layer of the stmt-graft 10.
The porous outer layer 12 can be generally cylindrical. The porous outer layer
12
can be made of any suitable porous biocompatible material, either
bioabsorbable
(i.e. biodegradable) or biostable (i.e. non-biodegradable) in nature.
Representative
examples of materials that can be used include, but are not limited to, any
polymeric material including porous polyurethanes (e.g. Thoralon~, available
from Thoratec Corporation, Pleasanton, California), ePTFE, PET, alphitic
6
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
polyoxaesters, polylactides, polycaprolactones, and hydrogels. "Hydrogel" is
intended to include a cross-linked polymer, via covalent, ionic, or hydrogen
bonding, to form a three-dimensional open lattice structure which is capable
of
entrapping water molecules to form a gel. Examples of hydrogels include non-
permissive hydrogels such as anionic hydrogels (e.g., alginate or carageenan)
and
"solid" hydrogels (e.g., agarose or polyethylene oxide).
In various embodiments of the stmt-graft 10, therapeutic substances can
also be contained within the porous outer layer 12 for sustained release of
the
substrate subsequent to the implantation procedure. Further, the porous outer
layer 12 can be made from any number of sub-layers, each having a different
porosity. As illustrated in Figure 3, the outer layer 12 can be made from
three
sub-layers. A first sub-layer 30 can have a first porosity and can border the
intima
during use. A second sub-layer 34 can have a second porosity. The third sub-
layer 36 can have a third porosity. A plurality of sub-layers made with
different
1 S porosities can be useful when encouraging different amounts of cell
ingrowth
and/or different drug release kinetics and rates for the optionally embedded
drugs.
The porous outer layer 12 can have a thickness of about 10 microns (0.39
mils) to about 500 microns (20 mils), more narrowly of about 50 microns (2.0
mils) to about 75 microns (3.0 mils). The outer layer 12 can have a void-to-
volume from about 40% to about 90%, more narrowly from about 70% to about
80%, for example about 76%, and a pore diameter from about 1 micron (0.039
mils) to about 400 microns (16 mils), more narrowly from about 1 micron (0.039
mils) to about 75 microns (3.0 mils), including the range of about 1 micron
(0.039
mils) to about 38 microns (1.5 mils). "Void-to-volume" is defined as the
volume
of the pores divided by the total volume of the layer including the volume of
the
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
pores. Void-to-volume can be measured using the protocol described in AAMI
(Association for the Advancement of Medical Instrumentation) VP20-1994,
Cardiovascular Implants - Vascular Prosthesis section 8.2.1.2, Method for
Gravimetric Determination of Porosity. The porosity of the porous outer layer
12
is illustrated by a scanning electron microscope (SEM) image of the surface
shown in Figure 4.
The porous outer layer 12 can function as a platform for allowing intimal
growth, anchoring the stmt-graft 10 to the vascular intima 32. After
implantation
of the stmt-graft 10, especially implantation in blood vessels, vascular
intima 32
can grow into the pores of the porous outer layer 12. Substantially all of the
volume of the pores of the porous outer layer 12 can be filled with intimal
ingrowth. If vascular intima ingrowth is not desired, the pores can be made
from
biophobic material or alternatively coated with a chemical that inhibits cell
growth,
such as non-permissive hydrogels including anionic and "solid" hydrogels.
Having the stmt-graft 10 not anchor to the vessel wall can also be helpful,
especially when the stmt-graft 10 is temporary or otherwise intended to be
removed. Anchoring, however, can help to prevent migration of the stmt-graft
10
after implantation within the body vessel.
The porous outer layer 12 also provides the stmt-graft 10 with a lubricious
surface to significantly decrease adhesion of the material of the porous outer
layer
12 to itself while collapsed (e.g. when pinched and folded or radially
compressed)
and reduce the degree of friction between the stmt-graft 10 and a delivery
device.
The decreased adhesion and reduced friction can be especially beneficial when
the
non-porous middle layer's material adheres easily to itself or to the inner
surface
of the delivery device.
s
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
The porous outer layer 12 can also add drug delivery functionality to the
stmt-graft 10. The porous outer layer 12 can be coated or its pores embedded
with any number of drugs. Bioabsorbable chemicals can also be added to the
embedded drugs to increase or retard drug delivery rates. The bioabsorption
rate
of the mixture of the bioabsorbable chemical and the drugs can lie between the
bioabsorption rates of the drug by itself and that of the bioabsorbable
chemical,
thereby speeding or retarding the release rate of the drug. Specific, non-
limiting
examples of chemicals that can alter drug release rates include alphitic
polyoxaesters, polylactides, polycaprolactones, and combinations thereof.
The stmt-graft 10 can release pharmaceuticals that prevent implant
rejection, counter atherosclerosis and/or restenosis, promote angiogenesis,
treat
anaphylactic shock, or for other suitable treatment or diagnose purposes.
These
drugs can be classified as anti-inflammatory, anti-proliferative, anti-
migratory,
antibiotic, anti-adhesion, and anti-platelet, among others. Drug delivery by
the
stmt-graft 10 can also work symbiotically with the anchoring function
discussed
above by encouraging intimal cell growth in the pores of the porous outer
layer 12.
NON-POROUS MIDDLE LAYER
The non-porous middle layer 14 can be attached to the porous outer layer
12 and the porous lumenal layer 16. Figure 5 illustrates the non-porous middle
layer 14 encapsulating the stmt 18 to provide a seamless polymer layer in
which
the stmt 18 is disposed. Accordingly, the non-porous middle layer 14 can be
configured to have no gaps or pockets located around the circumferences of the
struts 20, between the polymer layer and the surface of the struts 20.
9
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
The non-porous middle layer 14 can be made from any suitable non-
porous material that can function to prevent protrusion of the stmt 18 from
the
stmt-graft 10, block intimal growth, prevent prolapse of the vessel wall (with
some help from the outer and lumenal layers 12 and 16), and, if desired, block
drug delivery from the porous outer layer 12 to the lumen 28 and/or from the
porous lumenal layer 16 to the intima. Representative examples of materials
for
the non-porous middle layer 14 include, but are not limited to, any polymeric
material including polyurethanes (e.g. Thoralon~), PTFE, alphitic
polyoxaesters,
polylactides, and polycaprolactones.
The non-porous middle layer 14 can have a thickness of about 10 microns
(0.39 mils) to about 200 microns (7.9 mils), more narrowly of about 50 microns
(2.0 mils) to about 75 microns (3.0 mils). The lack of porosity in the non-
porous
middle layer 14 can be defined as a void-to-volume of less than about 5%,
including less than about 1%. The lack of porosity of the non-porous middle
layer
1 S 14 is illustrated by an SEM image of the surface shown in Figure 6.
POROUS LUMENAL LAYER
The porous lumenal layer 16 can be the inner-most radial layer of the
stmt-graft 10. The porous lumenal layer 16 can be attached to the non-porous
middle layer 14. The porous lumenal layer 16 can be made of any suitable
porous
biocompatible material, either bioabsorbable (i.e. biodegradable) or biostable
(e.g.
non-biodegradable) in nature. Examples of appropriate materials can be the
same
as the outer porous layer 12. Similar to the outer porous layer 12, the porous
lumenal layer 16 can be designed in sub-layers made of different porosity.
io
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
The porous lumenal layer can have a thickness of about 10 microns (0.39
mils) to about 500 microns (20 mils), more narrowly of about SO microns (2.0
mils) to about 75 microns (3.0~ mils). The lumenal layer 16 can have a void-to-
volume from about 40% to about 90%, more narrowly from about 65% to about
80%, for example about 72%, and a pore diameter from about 1 micron (0.039
mils) to about 400 microns (16 mils), more narrowly from about 1 micron (0.039
mils) to about 75 microns (3.0 mils), including the range of about 1 micron
(0.039
mils) to about 38 microns (1.5 mils). The porosity of the porous lumenal layer
16
is illustrated by an SEM image of the surface shown in Figure 7.
The porous lumenal layer 16 can be used for drug delivery by being coated
with drugs or having drugs embedded in the matrix. In blood vessels, the
porous
lumenal layer 16 can deliver drugs directly to the bloodstream in the lumen.
The
porous lumenal layer 16 can also function as a thromboresistant surface. The
porous lumenal layer 16 can be coated or embedded with one or more
thromboresistant chemicals such as heparin, prostaglandin, hirudin, urokinase,
streptokinase, a sulfated polysaccharide, albumin, fibronectin, laminin, a
tissue
plasminogen activator, collagen, gelatin, hyalraunic acid, and combinations
thereof.
STENT
As illustrated in Figures 1 and 2, the stmt 18 can be entirely surrounded by
the non-porous middle layer 14. The stmt 18 can have a generally circular
cross-
section or any other functional cross-sectional geometry such as oval,
hexagonal
or octagonal. Referring to Figures 8A, 8B, and 8C, the stmt 18 can be made
from
a plurality of interconnected (as shown in Figures 8A and 8B) or disconnected
(as
a
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
shown in Figure 8C) struts 20. Junctures between the struts 20 can occur at or
between the ends of the struts 20. The junctures can be mechanical crimps,
welds,
or solder points. The stmt 18 can also be machined or etched from a metal
cylinder.
The struts 20 can be straight, curved, or angled. The spaces 22 between
the struts 20 can form squares, circles, rectangles, diamonds, as shown in
Figure 1,
hexagons, as shown in Figure 8A, or any other functional geometry. Figure 9
illustrates an embodiment of a single strut 20 that has been cut and
flattened. The
strut 20 can have a strut height 37 from about 0.005 mm (0.0002 in.) to about
0.05
mm (0.002 in.), for example about 0.015 mm (0.0006 in.). The strut 20 can have
a
strut width 39 from about 0.05 mm (0.002 in.) to about 1 mm (0.04 in.), for
example about 0.1 S mm (0.0059 in.). The strut 20 can have a strut depth 41
from
about 1 mm (0.4 in.) to about 10 mm (4 in.), more narrowly about 2.5 mm (0.098
in.) to about 5 mm (0.2 in.). The strut can also have a strut inner radius 43
from
about 0.05 mm (0.002 in.) to about 0.5 mm (0.02 in.), for example 0.2 mm
(0.008
in.). The strut 20 can have a number of crowns 45 (e.g., from about three to
about
ten, including about five to about seven). Any number of struts 20 can be
used,
including the range from about three to about 20, more narrowly about seven.
As shown in Figure 10, disconnected struts 20 can be held in place by the
middle layer 14. The layers 12, 14, and 16 at the ends of the stmt-graft 10
can
also be trimmed to fit the shape of the struts 20, as illustrated in Figure
10, or
trimmed to have generally straight ends, as illustrated by Figure 1. The
spaces 22
between the struts can be small enough or the non-porous middle layer 14 (in
combination with the porous lumenal layer 16 and porous outer layer 12) can be
strong enough to prevent prolapse. In one embodiment, the ratio of the area
12
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
covered by the struts 20 to the area of the spaces 22 between the struts 20
can be
lower than 15%. The stmt 18 can be longitudinally straight or curved with any
number of radii of curvature to fit curved body vessels. The stmt 18 can also
be
bifurcated as shown in Figure 11. A bifurcation angle 38 is the angle between
two
legs 40 and 42 of a bifurcating stmt 18. The bifurcation angle 38 can vary
from
about 1 ° to about 90°.
In one embodiment, the stmt 18 can be a Symphony~ nitinol stmt
(available from the Medi-Tech division of Boston Scientific Corporation,
Natick,
Massachusetts). The stmt 18 can be made from other materials including
tantalum alloys, cobalt chrome alloys (e.g., Elgiloy~), platinum/tungsten
alloys,
stainless steels and combinations thereof.
The stmt 18 can be foldable to facilitate minimally invasive delivery and
deployment of the stmt-graft 10. The accompanying layers 12, 14 and 16 of the
stmt-graft 10 can also be flexible enough to easily fold with the stmt 18
during
delivery and deployment. The method of folding the stmt-graft 10 can include
pinching the stmt-graft 10 along a longitudinal line and folding the stmt-
graft 10
over that line, as illustrated in Figures 12A-12E and described in detail
below.
As illustrated in Figure 12F and described in detail below, the stmt 18 can
also be radially expandable, such as balloon expandable, self expandable, or a
combination thereof. If a radially expandable stmt is used in the stmt-graft
10,
the outer, middle, and lumenal layers 12, 14 and 16 can bulge out from the
spaces
22 between the struts 20 in response to the reduced surface area of the stmt-
graft
10 when the stmt-graft 10 is radially compressed in preparation for delivery.
13
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
The stmt 18 can include radiopaque markers that improve visibility of the
stmt 18. Alternatively or in addition to separate radiopaque markers, the
struts 20
can themselves be made of a radiopaque material. A radiopaque material can be
incorporated into the struts 20, or a radiopaque material can be coated on the
struts
20.
METHOD OF USE
PINCHING & FOLDING
Figures 12A-12C illustrate an embodiment of a method of folding the
stmt-graft 10 in preparation for delivery. Figure 12A illustrates an
embodiment
of the stmt-graft 10 in a normal or relaxed state. In Figure 12B, a force,
shown by
the arrows, can be applied to the stmt-graft 10 by radial squeezing from two
substantially opposite sides of the stmt-graft 10. This force causes a pinch
in the
stmt-graft 10. The pinch can extend longitudinally along the substantially
entire
length of the stmt-graft 10. The stmt-graft 10 on either sides of the pinch
can
form rounded lobes 52 and 54. The lobes 52 and 54 also can extend
longitudinally along about the substantially entire length of the stmt-graft
10.
Figure 12C illustrates the stmt-graft 10 in a pinched and folded state. In
this state, the stmt-graft 10 can be folded at the pinch along the
substantially
entire length of the stmt-graft 10. This folding can cause the lobes to be
pressed
and flattened on each other. The pinched and folded stmt-graft 10, as
illustrated
in Figure 12C, has a smaller cross-sectional area compared with the relaxed
stent-
graft 10, as illustrated in Figure 12A to facilitate delivery of the stmt-
graft 10.
Figures 12D and 12E illustrate another embodiment of the method of
folding the stmt-graft 10. Figure 12D illustrates the stmt-graft pinched,
shown by
14
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
the arrows, along three lines to create three lobes 52, 54, and 56. As
illustrated in
Figure 12E, the three lobes 52, 54 and 56 can then be folded upon each other.
Accordingly, the stmt-graft 10, after pinching and folding, can be inserted
into a delivery device, which would allow the stmt-graft 10 to be delivered
into
lumens with small cross-sectional areas. Release of the foldable stmt-graft 10
from the delivery device causes the stmt-graft 10 to regain its original
relaxed
shape of Figure 12A.
RADIALLY COMPRESSING
Figure 12F illustrates a radially compressible embodiment of preparing the
stmt-graft 10 for delivery. The radially expandable stmt-graft 10 can be
balloon
expandable or self expandable. In one embodiment, the radially expandable
stent-
graft 10 can be compressed by applying two or more inward radial forces, shown
by the arrows, on the stmt-graft 10. Because of the radially compressible
construction of the stmt 18, several embodiments of which are known to one
having ordinary skill in the art, the stmt-graft 10 collapses to a smaller
diameter.
When the stmt-graft 10 is radially compressed, the layers 12, 14, and 16
can be flexible enough to collapse into the center of the stmt-graft or extend
out
from the stmt-graft 10 forming numerous bulges 57. The bulges 57 need not be
longitudinally continuous as shown in Figure 12F, and can generally mimic the
shape of the voids 22 in the stmt 18.
The radially compressible stmt-graft 10 can be deployed via any suitable
delivery device, such as a dilatation catheter. The stmt-graft 10 can be
inserted
into a body vessel by any method known to one having ordinary skill in the
art. A
typical method for stmt-graft insertion includes compressing or folding of the
is
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
stmt-graft 10 and loading it onto a delivery catheter or delivery guidewire.
The
delivery catheter or guidewire can then be fed through a percutaneous delivery
device, such as an introducer or trocar, into the vasculature. Delivery can
also be
made without a percutaneous delivery device when the stmt-graft 10 is deployed
to an easily accessible location such as the esophagus.
METHOD OF MANUFACTURE
All of the compositions can be prepared by conventional methods where
all components are combined then blended. For example, a predetermined
amount of a polymer or a combination of polymers is dissolved in a solvent or
a
combination of solvents in, for example, an anhydrous condition at ambient
pressure. If necessary, gentle heating and agitation, such as by stirring, can
be
employed to effect dissolution of the polymer. A solvent is defined as any
fluid
capable of placing the polymer into a solution at the desired concentration.
POROUS LUMENAL LAYER
An inert (e.g., glass) mandrel can facilitate manufacturing of the stmt-graft
10. In one embodiment, the mandrel can be 6 mm (0.24 in.) in diameter and can
be cleaned before manufacturing with isopropyl alcohol. The mandrel can be
immersed in a first composition or, alternatively, the mandrel can be sprayed
with
the first composition for forming the porous lumenal layer 16.
The first composition can constitute at least one of the aforementioned
polymers admixed with a first solvent. Any suitable solvent for the polymer
can
be used as the first solvent including alcohols and aromatic hydrocarbons. One
specific example of a suitable solvent is dimethyl acetamide (DMAC). Using
16
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
Thoralon~ as the polymer and DMAC as the solvent, the composition can
comprise about 5% to about 40% polymer by weight. Different levels of polymer
within the range can be used to fine tune the viscosity needed for any given
process. The first composition can include less than 5% polymer for some spray
application embodiments. In one embodiment where the mandrel is immersed in
the first composition, the first composition can be about 14% polymer by
weight.
Porosity can be introduced by adding water-soluble particles, such as salt,
to the composition before the composition is applied to the mandrel. In one
embodiment, the particles can be mixed into the composition with a spinning
blade mixer for about an hour under ambient pressure and in a temperature
range
of about 18° C to about 27° C. The particles can then be
extracted by soaking the
dried layer in distilled water and dissolving the particles, leaving pores
behind.
The resulting void-to-volume can be substantially equal to the ratio of salt
volume
to the volume of the polymer plus the salt. The resulting pore diameter can
also
be substantially equal to the diameter of the salt grains. Extraction can
occur
through a variety of methods known to those having ordinary skill in the art,
including soaking in substantially still water at 60° C for one hour
while on a
mandrel, and soaking in substantially still water at 60° C for one hour
while off
the mandrel. Extraction can occur once all the layers and the stmt have been
applied. The first composition can have an amount of salt of about 10 to about
20
times, for example about 14 times, the amount of polymer by weight.
In one embodiment, the mandrel can be immersed in the first composition
at a speed of about 70 cm/min (28 in./min) through a die (having, for example,
a
i7
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
diameter of about 6.76 mm (0.266 in.)). Subsequent to the application of the
first
composition, the first solvent can be removed or allowed to evaporate to form
a
film layer of the polymer on the mandrel. Evaporation can be induced by
application of heat treatment, for example, about 5 minutes to about 24 hours
in an
oven at about 25 ° C to about 80 ° C. For example, heat
treatment can be
conducted at about 60° C for about 20 minutes at ambient pressure.
Alternatively,
vacuum conditions can be employed. The process of application of the first
composition and removal of the first solvent can be repeated to form the
porous
lumenal layer 16 of any suitable thickness.
NON-POROUS MIDDLE LAYER AND STENT
Subsequent to the formation of the porous lumenal layer 16, a second
composition can be applied to the porous lumenal layer 16 for deposition of
the
non-porous middle layer 14 by spraying or immersing the mandrel. The second
composition can constitute at least one of the aforementioned polymers for the
non-porous middle layer 14 admixed with a second solvent. The second solvent
can be the same as or different than the first solvent. The second solvent can
wet
the lumenal layer 16 to aid bonding with the middle layer 14. The possible
ratio
of polymer to solvent for the second composition can be the same as the ratio
for
the first composition. In one embodiment where the mandrel is immersed in the
second composition, the second composition can be about 24% polymer by weight.
In one embodiment, the step of removing the solvent of the porous
lumenal layer 16 need not be taken to a completion, so as to provide a porous
is
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
lumenal layer 16 with a semi-solid surface. The semi-solid surface can provide
a
better adhesive tie between the lumenal layer 16 and the middle layer 14, in
essence, eliminating a distinct seam between the two layers 14 and 16.
In one embodiment, the mandrel can be immersed in the second
composition at a speed of about 70 cm/min (28 in./min) through a die (having,
for
example, a diameter of about 6.76 mm (0.266 in.)). Subsequent to the
application
of the second composition, the second solvent can be removed or allowed to
evaporate to form a film layer of the polymer on the lumenal layer 16.
Evaporation can be induced by the application of heat treatment, for example,
about 5 minutes to about 24 hours in an oven at about 25° C to about
80° C. For
example, then heat treatment can be conducted at about 60° C for 60
minutes at
ambient pressure. Alternatively, vacuum conditions can be employed.
Following the formation of a layer of the non-porous middle layer 14, the
stmt 18 can be placed on the mandrel and securely positioned on the non-porous
1 S middle layer 14. The second composition can then be applied again to
encapsulate the sent 18. In one embodiment, this second application of the
second
composition can be performed by immersing the mandrel in the second
composition at a speed of about 70 cm/min (28 in./min) through a die (having,
for
example, a diameter of about 7.24 mm (0.285 in.)).
Subsequent to the application of the second composition for encapsulating
the stmt 18, the second solvent can be removed or allowed to evaporate.
Evaporation can be induced by application of heat treatment, for example,
about 5
minutes to about 24 hours in an oven at about 25° C to about 80°
C. For example,
19
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
the heat treatment can be conducted at about 60° C for about 30 minutes
at
ambient pressure. Alternatively, vacuum conditions can be employed. The
process of application of the second composition and removal of the second
solvent can be repeated to form the non-porous middle layer 14 of any suitable
thickness.
The expanded shape of the stmt 18 can be pre-set in an annealing process
before the stmt 18 is positioned on the mandrel. Prior to positioning the stmt
18
on the non-porous middle layer 14, the stmt 18 can be mounted on a mandrel
simulating the desired final shape of the stmt 18. The stmt 18 can then be
heated
for a time and at a temperature to increase grain size and then cooled to
recrystalize the stmt material in a desired phase. The mechanical properties
of the
stmt 18, including modulus of elasticity and plateau stress, can vary based on
the
heat treatment time and temperature. The stmt material and dimensions can also
be determinative of the annealing time and temperature. For example, a nitinol
stmt on a reshaping mandrel can be heat treated at 460° C for 15
minutes. A
nitinol stmt on a reshaping mandrel can, however, also be heat treated at
460° C
for 5 minutes, thus producing different mechanical characteristics of the stmt
including a higher modulus of elasticity and plateau stress than the stmt
heated for
15 minutes. Annealing times and temperatures for different materials and
producing different results are known to one having ordinary skill in the art.
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
POROUS OUTER LAYER
Subsequent to the formation of the non-porous middle layer 14, a third
composition can be applied to the non-porous middle layer 14 for forming of
the
porous outer layer 12. The third composition can constitute at least one of
the
aforementioned polymers for the porous outer layer 12 admixed with a third
solvent. The third solvent can be the same as or different that the first or
second
solvent. The third solvent can wet the middle layer 14 to aid bonding with the
outer layer 12. The possible ratio of polymer to solvent for the third
composition
can be the same as the ratio for the first composition. In one embodiment
where
the mandrel is immersed in the third composition, the third composition can be
about 10% polymer by weight.
The third composition can also include particles to form pores. The third
composition can have an amount of salt about 1 to about 10 times, for example
about 6 times, the amount of polymer by weight.
In one embodiment, the mandrel can be immersed in the third composition
at a speed of about 70 cm/min (28 in./min) through a die with about a 7.24 mm
(0.285 in.) diameter. Subsequent to the application of the third composition,
the
third solvent can be removed or allowed to evaporate to form a film layer of
the
polymer on the mandrel. Evaporation can be induced by application of heat
treatment, as described for the first composition. Alternatively, vacuum
conditions can be employed. The process of application of the third
composition
and removal of the third solvent can be repeated to form the porous outer
layer 12
of any suitable thickness.
21
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
COATINGS AND DRUGS
The stmt-graft 10 can also be coated on the lumenal side or the outer side
by spraying with or dipping in coating chemicals which can be mixed in a
removable solvent. Lubricants can be incorporated in coatings including
silicones,
polyvinyl pryoladone, and polypropylene oxide (PPO), and any other bio-
compatible lubricants known to one having ordinary skill in the art. Drugs may
also be incorporated as a coating or embedded in the porous layers 12 and 16.
The drugs can be in dissolution, either saturated or supersaturated, within
the
solvent and polymer composition or suspended in fine particles. Alternatively,
drugs can be physically incorporated into the pores of the outer layer 12 and
the
lumenal layer 16.
EXAMPLES
The invention will be better understood by making reference to the
following examples which are being provided by way of illustration and are not
intended to unduly limit the scope of the invention. In each example, an
embodiment of the stmt-graft was tested for different characteristics. The
stent-
grafts used in the examples were Symphony~ nitinol stems coated with an
approximately 110 micron thick porous lumenal layer, an approximately 135
micron thick non-porous middle layer, and an approximately 205 micron thick
porous outer layer, all of which were made from Thoralon~.
EXAMPLE 1 - DURABILITY TESTING
Three stmt-grafts were loaded into lumens of mock arteries that had radial
compliance similar to human arteries (e.g., 5-7% radial compliance) and
subjected
zz
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
to accelerated durability testing. Durability testing was performed in an
EnduraTEC testing system (available from EnduraTEC Systems Corp.,
Minnetonka, Minnesota) filled with water at 37°C. Pressure was cycled
from 80
mmHg diastolic to 120 mmHg systolic at a rate of 40 Hz for 56 hours. This is
equivalent to 77 days at a heart rate of 72 beats per minute. At the
completion of
the durability run, each stmt-graft was visually inspected at 40x
magnification for
tears in the covering, stmt protrusion, delamination of the covering, stmt
failure
or any other obvious device failure. No failures were evident in any of the
stent-
grafts at the completion of the testing.
EXAMPLE 2 - DEPLOYMENT TESTING
Experiments to evaluate the delivery systems and their ability to properly
deploy the stmt-graft were performed in a mock artery with 5% to 7% radial
compliance in a flow loop with a lOF sheath introducer (available from Cordis
Corp., Miami, Florida). A Thoratec~ 14086 ventricular assist device (VAD) gave
a flow rate through the mock arteries between 180 and 220 ml per minute
through
the target vessel at 72 beats per minute. Three stmt-grafts were loaded into
separate delivery systems and steam sterilized for 35 minutes at 120°
C.
To simulate in vivo deployment conditions, deployments were performed
with a covering over the mock arteries to blind the operator during the
delivery.
Each stmt-graft was deployed through the introducer into a mock artery by
advancing the introducer into position and retracting an outer sheath on the
introducer. The introducer was then withdrawn. If the delivery system did not
23
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
completely deploy the device or was not able to be withdrawn, deployment was
considered a failure. A visual inspection determined that all three devices
deployed properly.
EXAMPLE 3 - MIGRATION TESTING
Following the deployment testing, ~in the same system, the location of each
stmt-graft was marked on the outer vessel and flow continued for three days.
If
any movement was noted, the test was considered a failure. At the end of
testing
the location of each device was determined by visual inspection and no
migration
was evident.
EXAMPLE 4 - METAL ION OXIDATION (MIO) TESTING
MIO testing was performed to determine if Thoralon ~ would degrade in
the presence of nitinol. The MIO testing used both negative (theoretically no
damage) and positive (theoretically severe damage) controls along with the
test
samples (nitinol stems encapsulated within a middle layer of Thoralon~, but
with
no outer or inner layer). Samples were immersed in a solution of 3% hydrogen
peroxide at 37°C for extended periods of time. Degradation was assessed
through
visual examination and molecular weight analysis. If degradation occurred, the
molecular weight of the samples would decrease and stress cracks in the
polymer
would form. Samples were removed and tested every two weeks. Testing out to
15 weeks showed degradation of the positive controls while the test stmt-
grafts
and negative controls showed no evidence of degradation.
24
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
EXAMPLE 5 - ANIMAL STUDY
Three stmt-grafts were tested in the carotid arteries of three sheep along
with three control stems for 30 days. The effect of the stmt-graft to maintain
a
dilated vessel, prevent thrombus formation, promote ingrowth of intima, and
remain structurally intact, among other characteristics, is demonstrated by
these in
vivo studies. Table 1 summarizes the animal study.
TABLE 1
Animal Carotid pre-Implantpre-Explant
Number Vessel D(~jer Diameter Test Article
(mm)
Right 5.0 5.5-6.0 Stent-graft
1
Left 4.8 S.5-6.0 Bare stmt
Right 4.8 5.7 Bare stmt
2
Left 5.3 S.5 Stent-graft
The animal studies were performed at Covance Research products (CRP)
under IACUC protocol IAC-578. Angiograms of the animals' carotids were first
obtained. The carotids were then separated from the surrounding tissue and the
blood flow through the carotids was constricted. Then the carotids were
accessed
by a 9F introducer sheath in an incision about 7 cm in length and about 15 cm
distal to the deployment site. Stent-grafts of 6 mm internal diameter were
then
implanted and deployed into each animal's larger carotid using a stmt-graft
delivery system. The stmt-grafts were placed in the larger of the two carotids
in
each animal to allow for more accurate sizing. The delivery system and
introducer sheath were then removed. The puncture site was then closed using 7-
0
prolene ensuring a good closure with no leakage, and post-implant angiograms
were taken. The animals were maintained on a standard diet and care and give
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
daily aspirin for 30 days. After 30 days, angiograms were taken again, vessel
diameter measurements were obtained, the animals were euthanized and the
carotid arteries and test devices were removed, preserved in formalin,
sectioned
and stained.
In Animal 1, pre-explant diameter data taken from the angiogram
suggested vessel diameters on both sides larger than the maximum stmt
diameter.
Thus this data was disregarded. Internal diameters read from histological
sections
show internal diameters at explant of about 5.5 mm to about 6.0 mm.
Figure 13 shows a 40 times magnified close-up of the histological slide for
the vessel and a control stmt of Animal 1. A portion of an intima 32 of a
vessel is
shown with cross-sections of the stmt 18 pressed against it. Both cross-
sections
of the stmt 18 are surrounded by large masses of thrombi 58. This control
result
shows an occurrence of thrombi 58 with the uncoated stmt. Furthermore, there
is
no ingrowth of the intima 32 into the stmt 18. The stmt 18 is even separated
from
the intima 32 by the thrombi 58. Signs of prolapse between the struts 20 of
the
stmt 18 are also present.
Figure 14 shows a 40 times magnified close-up of the histological slide for
the vessel and stmt-graft 10 of Animal 1. Figure 14 shows positive results.
Thrombi in the lumen along the surface of the porous lumenal layer 16 are not
detectable, especially with respect to the control. In fact, the porous
lumenal layer
16 has no signs of tissue proliferation at all. Ingrowth of the intima 32
along the
outer porous layer 12 is plentiful, highlighted by the darkened color of the
outer
porous layer 12. Higher magnifications of the vessel also showed no
inflammatory reaction to the stmt-graft 10 and no platelet adhesion or other
signs
of thrombus formation. Further, there are no signs of prolapse along the
intima 32.
26
CA 02469744 2004-06-09
WO 03/051233 PCT/US02/38940
Animal 2 produced good pre-implant and pre-explant diameter
measurements. The diameter measurements shown above in Table 1 illustrate that
both the stmt-graft and the stmt significantly dilate the vessel, hold
structural
integrity, and prevent occlusion. Due to Animal 2 having a smaller carotid pre-
S implant diameter and only one size of the stmt and the stmt-graft available
for the
study, the stmt-graft was constricted so much that the cramped layers folded
slightly into the lumen. With a proper sized stmt-graft, this would probably
not
be a problem. Histological slides from Animal 2 concur with the results from
the
histological slides from Animal 1. Even with the minimal obstruction of the
lumen by the folded layers of the improperly sized stmt-graft, the porous
lumenal
layer 16 still had no signs of thrombi or other tissue proliferation. The
control
stmt, however, still produced thrombi. The porous outer layer 12 had good
ingrowth of the intima and prolapse with the stmt-graft was non-detectable,
yet
visible in the vessel with the control stmt. (Slides for Animal 2 are not
shown to
prevent misinterpretation due to distortion from air bubbles created during
slide
preparation and the folds of the layers into the lumen.)
Although the invention has been disclosed in terms of particular
embodiments and applications, one of ordinary skill in the art, in light of
this
teaching, can generate additional embodiments and modifications without
departing from the spirit of or exceeding the scope of the claimed invention.
Accordingly, it is to be understood that the drawings and descriptions herein
are
proffered by way of example to facilitate comprehension of the invention and
should not be construed to limit the scope thereof.
27
